CellTrans has achieved what no other company has: FDA approval for the first-ever allogeneic islet cell therapy— Lantidra—marking a watershed moment in the treatment of diabetes.
While most therapies manage the symptoms of type 1 diabetes, CellTrans is tackling the root cause by restoring the body’s ability to produce insulin naturally. Lantidra is created using donor-derived pancreatic islet cells that are isolated and processed under stringent FDA-compliant conditions. These cells are then infused into the patient’s liver via the hepatic portal vein. Once delivered, they begin functioning like native islet cells—monitoring blood glucose levels and releasing insulin in real time, effectively replicating the body’s own metabolic response.
“With Lantidra, our goal is to help people with type 1 diabetes and severe hypoglycemia reclaim their body’s ability to produce insulin, potentially freeing them from the burden of daily injections,” says José Oberholzer, Founder, President and CMO.
The fact that CellTrans achieved this as a self-funded startup makes the story even more exceptional. With no outside capital and a lean, tightly knit team, it successfully navigated the regulatory and scientific gauntlet, including Chemistry, Manufacturing and Controls (CMC) strategy, clinical application development, regulatory interactions, Biologics License Application (BLA) submission and FDA approval. This level of end-toend execution is rare, even among large, well-funded biotech companies.
Firsthand experience of building and navigating the entire development lifecycle now drives CellTrans’s work beyond its products. Through its contract research division, it helps other innovators bring first-in-class cell and biomaterial-based therapies to market. Its services cover the full spectrum: from early-stage proof-of-concept to IND-enabling studies, with deep expertise in in vitro and preclinical in vivo models, cell functionality and biomaterial integration for regenerative and therapeutic applications.
Unlike traditional CROs with siloed departments and slow handoffs, CellTrans runs as a unified, agile team. The same scientists who help design your studies stay involved through execution, ensuring continuity, speed and quality. This structure reduces miscommunication, accelerates iteration and helps generate cleaner, more decision-ready data.
At the core of this model is adaptability. CellTrans understands that no two clients face the same set of challenges. Whether the hurdle is budget constraints, tight timelines or complex technical demands, the team tailors its approach to meet the reality of each program.
-
With Lantidra, our goal is to help people with type 1 diabetes and severe hypoglycemia reclaim their body’s ability to produce insulin, potentially freeing them from the burden of daily injections
At the core of this model is adaptability. CellTrans understands that no two clients face the same set of challenges. Whether the hurdle is budget constraints, tight timelines or complex technical demands, the team tailors its approach to meet the reality of each program.
“Our journey made us resourceful,” says James McGarrigle, COO. “We’ve lived every part of the development lifecycle—viability, functionality, immune compatibility and tight budgets. That experience lets us de-risk our clients’ programs before problems even surface.”
A recent example is a client developing an immune cell therapy for advanced peritoneal cancer who turned to CellTrans for full-spectrum support. The challenges were complex, spanning concept development, preclinical planning, pharmacodynamic modeling and regulatory strategy. CellTrans helped define proof-of-concept milestones in a large-animal model and laid out a comprehensive path for clinical translation. With a clear strategy, hands-on execution and early alignment with FDA expectations, the client reached IND and launched a trial in just two and a half years—a process that typically takes five.
Support also extends into the post-approval world. CellTrans helps clients prepare for real-world use—from manufacturing scale-up to insurance coverage, reimbursement, coding and patient access.
-4.jpg){kind=spacer}
Not just innovation, but execution—that’s where CellTrans distinguishes itself. Lantidra isn’t simply a scientific breakthrough; it’s evidence of a company capable of advancing complex therapies all the way to market. As CellTrans expands into areas such as neuroscience and oncology, it carries that same discipline forward, working not only on its pipeline but supporting others navigating the challenges of cell therapy from early development through post-approval.
It’s the perspective that comes from doing it all firsthand. As both a licensed manufacturer and a strategic partner, CellTrans offers more than a service. It provides alignment, insight and a proven ability to see a therapy through. That’s the difference it brings to every collaboration—and the reason more breakthrough therapies are finding their path forward with CellTrans by their side.
Diabetes Cell Therapys Clinical Standard
Diabetes care has entered a more demanding stage in which executives evaluating cell-based therapies must look beyond glucose monitoring systems, insulin delivery devices and incremental management improvements. For patients with brittle type 1 diabetes who continue experiencing severe hypoglycemia despite intensive treatment, the key question is no longer whether another management layer can be added. Instead, organizations must determine whether a therapy pathway can restore meaningful insulin-producing function while satisfying the clinical, regulatory and operational demands associated with advanced biotechnology programs.
The field rewards operational discipline because scientific promise alone is insufficient. Islet-based therapies depend on coordinated donor sourcing, cell isolation, quality control, transplant logistics, immune compatibility management and long-term follow-up planning. Even a promising therapeutic concept can lose value if manufacturing variability weakens release standards or if clinical teams cannot reproduce reliable patient outcomes outside controlled studies. Executives should evaluate evidence quality, process maturity and reimbursement readiness as interconnected indicators rather than isolated checkpoints. A credible diabetes cell therapy partner must demonstrate biological expertise and the operational capability required to move that biology into practical patient care. For acquisition and partnership teams, the real test is whether the organization can translate technical complexity into clear decision-making frameworks. Data should explain potency, viability, engraftment rationale, immune-management considerations and patient-monitoring strategies in ways that research, finance and medical-affairs stakeholders can evaluate confidently.
Clinical positioning also matters. The strongest cell-based interventions are not designed to replace every diabetes therapy. Instead, they address a specific population: patients whose severe hypoglycemia remains inadequately controlled despite conventional treatment approaches. Precise patient selection strengthens clinical credibility, supports realistic payer discussions and improves coordination with transplant centers and referring physicians. Broad therapeutic claims are far less valuable than a clear explanation of which patients are likely to benefit, what outcomes are achievable and how long-term safety will be monitored after treatment.
Manufacturing and regulatory capability should receive equal attention. Cell therapies differ fundamentally from conventional pharmaceuticals because they involve living biological material whose function must remain intact from procurement through administration. Executives should prioritize organizations with controlled manufacturing environments, validated release testing, experienced quality oversight and established regulatory interaction history. These capabilities reduce uncertainty as therapies move from clinical evidence into institutional adoption and influence whether programs can scale responsibly without compromising consistency or patient safety.
The same principles extend into preclinical and translational support. Organizations evaluating diabetes cell therapy often require more than a single therapeutic product. They may also need expertise in disease models, functional assays, biomaterial testing, IND-enabling studies, clinical design strategy and post-approval planning. Strong partners connect these stages into a coherent development pathway so that early scientific evidence supports later regulatory and commercial decisions. Fragmented handoffs between providers can slow learning, dilute accountability and produce data that is scientifically interesting but operationally difficult to use.
CellTrans stands out for organizations focused on islet-based diabetes cell therapy. Its product, Lantidra, is an FDA-approved allogeneic pancreatic islet cellular suspension designed for adults with type 1 diabetes experiencing severe hypoglycemia despite intensive management. The company supports this therapy through cGMP manufacturing capabilities, clinical transplantation expertise and deep experience in islet quality assessment. CellTrans also provides services spanning in vitro islet assays, preclinical transplant models, biomaterial evaluation, regulatory strategy, clinical study design and IND-enabling support. For organizations seeking scientific depth combined with practical approval-pathway experience, CellTrans offers a focused and evidence-based route from islet biology to clinical application.
...Read more
Diabetes Cell Therapy Info
Q1
Why is CellTrans recognized among Top Diabetes Cell Therapy Companies?
CellTrans has gained strong recognition as a Diabetes Cell Therapy Company because it achieved the first FDA-approved allogeneic islet cell therapy for Type 1 diabetes. Its therapy Lantidra (donislecel) uses donor-derived pancreatic islet cells that are infused into the patient’s liver, where they begin producing insulin. This approach directly addresses the root cause of insulin deficiency rather than only managing blood glucose levels, which positions the company among leading innovators in Diabetes Cell Therapy Company advancements.
Q2
What makes CellTrans different from other Diabetes Cell Therapy Company approaches?
Unlike conventional diabetes treatments that rely on insulin injections or glucose monitoring devices, CellTrans focuses on functional cell replacement. Its Diabetes Cell Therapy Company model is built on isolating and transplanting viable islet cells that can respond naturally to blood glucose levels. This biological restoration approach allows selected patients with severe hypoglycemia to achieve long-term insulin independence in some cases, depending on immune response and transplant success.
Q3
How does Lantidra work within CellTrans’s Diabetes Cell Therapy Company platform?
Lantidra works by infusing purified pancreatic islet cells from deceased donors into the liver via the portal vein. Once inside the liver, these cells function similarly to pancreatic beta cells by sensing glucose levels and releasing insulin accordingly. As part of its Diabetes Cell Therapy Company model, CellTrans ensures these cells are processed under strict FDA-compliant conditions before transplantation, supporting both safety and functional performance in clinical use.
Q4
What role does clinical research play in CellTrans as a Diabetes Cell Therapy Company?
Clinical research is central to CellTrans’s operations, spanning preclinical development, IND-enabling studies and multi-phase clinical trials. As a Diabetes Cell Therapy Company, it integrates research directly with manufacturing and clinical execution. This includes in vitro testing, biomaterial integration studies and transplantation protocols that validate how islet cells behave in real biological environments. The company’s experience with full lifecycle development strengthens its ability to advance cell-based therapies efficiently.
Q5
How does CellTrans ensure quality and regulatory compliance in its Diabetes Cell Therapy Company operations?
CellTrans maintains strict compliance with FDA guidelines, particularly in Chemistry, Manufacturing and Controls (CMC) processes. Its Diabetes Cell Therapy Company framework includes validated isolation techniques, sterile processing environments and rigorous quality testing before cell release. Each Lantidra batch undergoes predefined release criteria to ensure safety, viability and functional insulin production capability before clinical use.
Q6
Why is CellTrans important in the future of Diabetes Cell Therapy Company innovation?
CellTrans plays a key role in advancing the future of diabetes treatment by moving beyond symptom management toward potential functional cure strategies. As a Diabetes Cell Therapy Company, it demonstrates how biological cell replacement can reduce or eliminate dependence on external insulin in select patients. Its continued work in islet transplantation and regenerative cell technologies positions it as a contributor to next-generation therapies for endocrine disorders.
